Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Whitehawk Therapeutics, Inc. (WHWK)

$3.71 -3.13% NASDAQ: WHWK · 15-min delayed
  • MORRISTOWN, New Jersey
  • Public · NASDAQ: WHWK
  • 23 employees
$183.5MMarket cap
$7.1MRevenue · FY2025
-$20.6MNet income
23Employees
WHWKNASDAQ
2021IPO

About Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$7.1M
Net income
-$20.6M
Total assets
$150.8M
Market cap
$183.5M
Gross margin
89.4%
Operating margin
-1601.1%
Net margin
-288.3%

Source: SEC EDGAR · updated Jun 7, 2026

FY 2025

Financial statements

Income statement

Revenue
$7.1M
Cost of revenue
$760.0K
Gross profit
$6.4M
Operating expenses
$120.8M
Operating income
-$114.4M
Income tax
$0
Net income
-$20.6M
EPS (basic)
$-0.33
EPS (diluted)
$-0.33

Balance sheet

Total assets
$150.8M
Current assets
$149.0M
Total liabilities
$14.5M
Current liabilities
$14.5M
Shareholders’ equity
$136.3M

Cash flow

Operating cash flow
-$97.4M
Investing cash flow
$11.9M
Financing cash flow
$94.4M
Net cash flow
$8.8M

Statements via Polygon.io (SEC filings)

NASDAQ: WHWK
$3.71 -3.13%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.60 $5.10

52-week range

Market cap
$183.5M
EPS (diluted)
$-0.33
Shares outstanding
55.3M
Open
Day range
Prev close
Volume
IPO date
Aug 27, 2021

Whitehawk Therapeutics, Inc. (WHWK) Stock Price

  • Reported a net loss of $20.6M in FY2025.
  • Gross margin of 89.4%, net margin -288.3%.
  • Trading 27% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Whitehawk Therapeutics, Inc..

Write a review
FAQ

Whitehawk Therapeutics, Inc.: frequently asked questions

Is Whitehawk Therapeutics, Inc. an American company?

Whitehawk Therapeutics, Inc. is a US-based company headquartered in Morristown, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Whitehawk Therapeutics, Inc. headquartered?

Whitehawk Therapeutics, Inc. is headquartered in Morristown, New Jersey, United States.

Is Whitehawk Therapeutics, Inc. publicly traded?

Yes — Whitehawk Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol WHWK on the NASDAQ.

What does Whitehawk Therapeutics, Inc. do?

Whitehawk Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →